Table 2.
Tumor response, PFS, and OS according to PD-L1 status.
| PD-L1–positive | PD-L1–negative | |||
|---|---|---|---|---|
| Group 1 | Groups 2 and 3 | Group 1 | Groups 2 and 3 | |
| Patients analyzed, n | 17 | 32 | 10 | 26 |
| ORR, n (%) | 4 (23.5) | 15 (46.9) | 3 (30.0) | 8 (30.7) |
| Median PFS, months (95% CI) | 5.4 (3.3–NR) | 9.7 (6.2–15.5) | 9.2 (8.3–NR) | 9.4 (6.5–14.6) |
| HR (95% CI) | — | 0.57 (0.3–1.2) | — | 0.97 (0.4–2.5) |
| Median OS, months (95% CI) | 10.5 (6.3–18.8) | 32.7 (17.7–NR) | 13.9 (12.6–NR) | 17.8 (13.1–NR) |
| HR (95% CI) | — | 0.34 (0.2–0.7) | — | 0.48 (0.2–1.2) |
Note: Group 1, chemotherapy on days 1 and 8; group 2, trilaciclib prior to chemotherapy on days 1 and 8; group 3, trilaciclib alone on days 1 and 8 and prior to chemotherapy on days 2 and 9. HRs are for comparisons between groups 2 and 3 combined and group 1.